MedPath

Tevogen Bio CEO Highlights Commitment to Patient Accessibility and Business Model

• Tevogen Bio's CEO, Dr. Saadi, reaffirmed his dedication to making therapeutics accessible to patients through the company's innovative business model. • The company's officers hold nearly 79% of outstanding shares, demonstrating confidence in Tevogen Bio's potential and long-term vision. • Tevogen Bio is advancing its ExacTcell™ technology to develop off-the-shelf T cell therapies for infectious diseases, cancers, and neurological disorders. • Tevogen Bio anticipates sharing updates on its pipeline, including a $1 billion oncology forecast for the launch year, indicating strong growth expectations.

Tevogen Bio's CEO and founder, Dr. Saadi, MD, MPH, has expressed his gratitude for the public support of the company's business model, which focuses on patient accessibility. This announcement comes amid updates on the company's pipeline and financial forecasts, including a $1 billion oncology forecast for the launch year.

Commitment to Accessibility

Dr. Saadi emphasized his commitment to bringing accessible therapeutics to market, highlighting the leadership team's retention of 100% of their equity. This decision reflects their confidence in the company's potential. "The leadership team’s retention of 100% of their equity reflects their confidence in the company’s potential," said Dr. Saadi.

Shareholder Confidence

As of June 30, 2024, officers of Tevogen Bio held nearly 79% of the company’s outstanding shares. According to Tevogen, any reported sales by officers were solely to satisfy tax obligations related to the vesting of restricted stock units and were not made at the discretion of the reporting officer.

ExacTcell™ Technology

Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified T cell therapeutics. The company's proprietary ExacTcell™ technology is designed to create accessible and disease-specific cellular immunotherapies. Tevogen Bio has been granted three U.S. patents, with nine additional patents pending, including two for Artificial Intelligence, and has filed 12 international applications. The company has also reported positive proof-of-concept clinical trial data for the first clinical product of its proprietary technology.

Pipeline and Future Expectations

Tevogen Bio is focused on addressing the unmet needs of large patient populations through precision T cell therapies for infectious diseases, cancers, and neurological disorders. The company anticipates sharing further details about its progress in the coming days, including updates on its pipeline and financial forecasts.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Lineage Cell Therapeutics Updates Shareholders on Progress and 2025 Outlook

Lineage Cell Therapeutics, a clinical-stage biotechnology company, has shared a letter with its stockholders detailing recent achievements, including advancements in its allogeneic cell therapy programs, and outlining its outlook for 2025. The company emphasizes its unique approach to cell transplantation, its financial strategy, manufacturing capabilities, and long-term goals, particularly focusing on its OpRegen® program for dry-AMD and other neurological cell transplant candidates.

Trogenix Launches Odysseus Platform for Precision Viral Immunotherapy in Cancer

Trogenix has emerged from stealth mode, introducing its Odysseus platform for precision cancer therapy, targeting aggressive tumors with enhanced selectivity.
The Synthetic Super-Enhancer (SSE) technology drives the Odysseus platform, enabling targeted expression of cytotoxic payloads and immune modulation, showing curative potential in preclinical studies.

Trogenix Launches Odysseus Platform for Precision Viral Immunotherapy in Cancer

Trogenix has emerged from stealth mode with its Odysseus platform, designed for precision targeting of aggressive cancers using synthetic super-enhancers.
The Odysseus platform delivers a multi-faceted attack on cancer cells, including targeted cell killing, immune modulation, and a 'Trojan Horse' approach to reawaken the immune system.

Imugene Expands CAR T-Cell and Oncolytic Virotherapy Trials in Australia and the US

Imugene is broadening its clinical trial programs for CAR T-cell therapy and oncolytic virotherapy across Australia and the United States.
The expansion aims to accelerate the development of novel cancer treatments, leveraging innovative immunotherapeutic approaches.

Evaxion Biotech Leverages AI for Vaccine Development in Cancer and Infectious Diseases

Evaxion Biotech utilizes its AI platform, AI Immunology, for rapid vaccine discovery and development, targeting cancer and infectious diseases.
The company's lead candidate, EVX-01, a personalized neoantigen vaccine, demonstrated a 69% overall response rate in a Phase II trial for metastatic melanoma.

Tevogen Bio's TVGN 489 Shows Promise in High-Risk COVID-19 Patients

Tevogen Bio's TVGN 489, an allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes immunotherapy, demonstrates promising results in a Phase I clinical trial.
The trial showed symptom improvement and viral elimination in high-risk COVID-19 patients, including those immunocompromised, with no disease progression or Long COVID development.

Vironexis' VNX-101 Cleared for Phase 1/2 Trial in CD19+ Acute Lymphoblastic Leukemia

Vironexis Biotherapeutics received FDA clearance for its IND application for VNX-101, an AAV-based gene therapy, enabling a Phase 1/2 trial for CD19+ acute lymphoblastic leukemia.
VNX-101 uses the TransJoin platform to express a bispecific T-cell engager, targeting CD19 on tumor cells and CD3 on T-cells to facilitate cancer cell killing.

Bill Gates Optimistic About Progress in M72 Tuberculosis Vaccine Clinical Trial

Bill Gates expressed optimism about the M72 tuberculosis vaccine clinical trial, anticipating a 70% efficacy in reducing the disease.
The ongoing Phase 3 trial, costing $500 million, is a collaboration between GSK, the Wellcome Trust, and the Gates MRI.

Adaptimmune's Journey to Pioneering TCR-T Therapy for Cancer Treatment

Adaptimmune, a biotech company founded in 2008, has made significant strides in developing T-cell receptor (TCR)-T therapies for cancer. Despite challenges and rocky collaborations with pharmaceutical giants like GSK and Astellas, Adaptimmune achieved a major breakthrough with the FDA approval of its first engineered TCR-T therapy, afami-cel, for treating metastatic or unresectable synovial sarcoma. This approval marks several firsts in the field of cell therapy, offering new hope for patients with rare solid tumors.

FDA Approves Krystal Biotech's Vyjuvek, a Topical Gene Therapy for Dystrophic Epidermolysis Bullosa

The FDA has approved Vyjuvek, Krystal Biotech's topical gene therapy, marking the first treatment of its kind for dystrophic epidermolysis bullosa.
Vyjuvek is approved for patients aged six months and older with either recessive or dominant forms of dystrophic epidermolysis bullosa.

Reference News

[1]
Tevogen CEO Expresses Gratitude for Unprecedented Public - GlobeNewswire
globenewswire.com · Oct 19, 2024

Tevogen Bio, a clinical-stage immunotherapy biotech, develops off-the-shelf T cell therapeutics for infectious diseases ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy